The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells
Gian Carlo Alghisi, Lionel Ponsonnet, Curzio Rüegg · 2009
Read The Integrin Antagonist Cilengitide Activates αVβ3, Disrupts VE-Cadherin Localization at Cell Junctions and Enhances Permeability in Endothelial Cells by Gian Carlo Alghisi, Lionel Ponsonnet, Curzio Rüegg (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004449.txt.
Description
A drug meant to block blood vessel growth had some surprising side effects on vessel walls, report Gian Carlo Alghisi, Lionel Ponsonnet, and Curzio Ruegg in PLOS ONE in 2009. The drug, cilengitide, blocks proteins called integrins that cells use to grip their surroundings. It was reported to suppress new vessel growth by causing vessel-lining cells to die.
Instead, the team found the drug switches on the integrin it targets, in a form called alphaVbeta3. It also pulls apart a joining protein, VE-cadherin, where cells meet, and makes vessel walls leakier. Those effects matter for any drug of this class. A blocker that partly acts like an activator may help some tumors, or help them in the wrong way, so the detail counts.
Catalog record
| CREATOR | Gian Carlo Alghisi, Lionel Ponsonnet, Curzio Rüegg |
|---|---|
| YEAR | 2009 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| LICENSE | Creative Commons Attribution License |
| RIGHTS | CC BY |
| SOURCE | PLOS ONE |
Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004449